Pfizer ends vaccine trial with 95% success rate, to apply for approval soon

Pfizer and BioNTech said they plan to submit the data to other regulatory agencies around the world.

Final results from Pfizer's Covid-19 vaccine trial showed its shot had a 95 per cent success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency US authorisation within days, it said on Wednesday. Pfizer said it expected the US FDA vaccine advisory committee to review and discuss the data in a public meeting that will likely be held in December.

The efficacy rate of the vaccine, developed by Pfizer and its German partner BioNTech, is the highest of any candidate in late-stage clinical trials so far. Global shares edged higher on